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Abstract
Objective
Our aim is to present the disease course, frequency of relapses and survival of juvenile and adult 
dermatomyositis (JDM/DM) patients.
Methods
Analysis was performed using data on 73 patients. The median follow-up for 38 JDM patients was 32
months and 78 months for 35 adult DM patients.
Results
23/38 JDM patients (60%) had monophasic, 12/38 (31.6%) had polycyclic and 3/38 (7.9%) had chronic
disease. Among children treated only with glucocorticoids, 12/20 (60%) had monophasic and 8/20
(40%) had polycyclic disease. 10/17 (58.8%) children, who required second-line immunosuppressive
agents, had monophasic and 4/17 (23.5%) had polycyclic disease. 18/35 DM (51.4%) patients had
monophasic, 13/35 (37.1%) had polycyclic, 1/35 (2.9%) had chronic disease and 3/35 (8.6%) had 
fulminant myositis. Among DM patients requiring only glucocorticoids, 12/20 (60%) were monophasic
and 8/20 (40%) were polycyclic. In patients requiring second-line immunosuppressive agents, 6/15
patients (40%) had monophasic and 5/15 (33.3%) had polycyclic disease. Among patients with 
polycyclic disease, the risk of relapse was higher during first year than later in the disease course. 
None of the JDM patients have died, while 4 disease-specific deaths occurred in adult patients. 
There was no significant difference between the survival of JDM and DM patients.
Discussion
There was no correlation between relapse-free survival and the initial therapeutic regimen. Many of 
our patients had polycyclic or chronic disease. As relapses can occur after a prolonged disease-free 
interval, patients should be followed for at least 2 years. Although we found a favourable survival rate,
further investigations are needed to assess functional outcome.
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Abbreviation used in this article:
AZA: azathioprine
CAM: cancer-associated myositis
CK: creatinine-kinase
CYA: cyclosporine A
CYC: cyclophosphamide
CI: confidence interval
DM: dermatomyositis
HRCT: high-resolution computerized
tomography
IIM: idiopathic inflammatory myopathy
ILD: interstitial lung disease
IVIG: intravenous immunoglobuline
JDM: juvenile dermatomyositis
LDH: lactate-acid dehydrogenase
MTX: methotrexate
OM: overlap myositis 
PM: polymyositis
Introduction
The idiopathic inflammatory myopath-
ies (IIMs) are systemic autoimmune di-
seases characterized by chronic muscle
inflammation resulting in progressive
weakness and cutaneous lesions (helio-
trope rash, Gottron’s papules, Gottron’s
sign and V-sign) in the case of dermato-
myositis. The frequent extraskeletal-
and extramuscular manifestations, main-
ly the involvement of the pulmonary,
gastrointestinal and cardiac systems,
considerably contributes to the morbid-
ity and mortality of the disease.
IIMs affect both children and adults. In
childhood, the most frequent subgroup
is juvenile dermatomyositis (JDM).
The first case of JDM was reported by
Potain (14). Children with JDM have a
better prognosis than adult DM patients.
The association of cancer with JDM is
rare (6,16). For the most frequent myo-
pathies, polymyositis (PM) and DM,
mortality was 50% within one year be-
fore the widespread use of glucocorti-
coids (1). In the past decades, earlier
diagnosis and more aggressive immu-
nosuppressive treatment regimens have
become the standard of care, so the sur-
vival of patients with IIMsha  progres-
sively improved worldwide (7, 18).
The goal of medical therapy is to pre-
vent acute muscular damage, chronic
muscular atrophy and contracture, to
prevent disease relapses, and last but
not least to restore at least in part the
patient’s quality of life (1,13). Treat-
ment of JDM/DM is based on immune
suppression with first-line agent gluco-
corticoids starting with a dose of 1-2
mg/kg/day of prednisolone or an equiv-
alent. This traditional therapy is effec-
tive in about 60-80% of patients with
juvenile or adult DM (1,8,1). Gluco-
corticoids are considered to be ineffec-
tive if after 3 months the muscular weak-
ness does not abate or the disease flares
again after a dose reduction (1). In
these cases or when severe side effects
occur, additional immunosuppressants
such as azathioprine (AZA), metho-
trexate (MTX), cyclosporine A (CYA),
intravenous immunoglobulin (IVIG)
and cyclophosphamide (CYC) (sec-
ond-line agents) can be used (10, 15,
16, 20). Up to 20-40% of myositis pa-
tients require not only glucocorticoids,
but other immunosuppressive therapy
as well. Recently many authors have
promoted the use of second-line drugs
early in the course of the illness along
with glucocorticoids (2,4,19), especi-
ally when the prognosis is considered
to be poor (Table I).
We report here the first study of 38
Hungarian JDM patients, in whom the
dis ase course, frequency of relapses
and survival were investigated. We
examined the relationship between the
type of initial treatment and the subse-
quent clinical course. Furthermore, we
compared our data on JDM patients
with data on adult primary, idiopathic
DM patients. To our best knowledge,
this constitutes one of the largest stud-
ies comparing the clinical course and
survival of juvenile and adult DM
patients published to date.
Methods
Patient selection
In this study, 38 consecutive juvenile
in- and out-patients were identified
who had been diagnosed, treated and
followed-up by the 2ndDepartment of
Disease course and survival of JDM and DM patients /A. Ponyi et al. 
51
Table I.Classical factors for a poor prognosis in juvenile and adult DM (refs. 5, 6, 7, 9).
l Acute, severe disease led to life threatening situation
l Severe dysphagia led to possible risk of aspiration
l Cardiac involvement
l Dysphonia
l Interstitial lung disease
l Vasculitis
l Positive anti-synthetase (anti-Jo-1) or anti-SRPautoantibody test
l Delay of diagnosis and treatment
l Inadequate treatment
l Older age
l Male sex
l African-American race
l Associated malignancy
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Pediatrics, Semmelweis University,
Faculty of Medicine; the 3rd Depart-
ment of Internal Medicine, University
of Debrecen; the National Institute of
Rheumatology and Physiotherapy and
Heim Pál Children’s Hospital. We com-
pared data on these JDM patients with
data on 35 adult primary, idiopathic
DM patients, who had been diagnosed,
treated and followed-up by the 3rd
Department of Internal Medicine, Uni-
versity of Debrecen. The diagnosis of
DM was made between January 1,
1976 and December 31, 2002. 
We analyzed the medical records retro-
s p e c t i v e l y, recording the following
data: age, sex, the time of diagnosis;
the type of clinical course and the date
of death or the end of follow-up; the
initial treatment and the treatment
which led to remission; and extraskele-
tal and extramuscular manifestations at
any time during the clinical course. We
decided not to analyze the parameter of
myositis-specific autoantibodies be-
cause this assay was not carried out in
all of the patients in the study. All pa-
tients were Caucasian. There were no
missing values among the investigated
factors in the dataset. Patients with ju-
venile or adult PM, with overlap myo-
sitis or cancer-associated myositis
(CAM) were excluded.
Diagnosis
In all cases the diagnosis of DM was
based upon the criteria defined by
Bohan and Peter (3):
1. Progressive, symmetrical weakness
of the proximal muscles;
2. Raised creatinine-kinase (CK) and
lactate-acid dehydrogenase (LDH)
enzyme activity in the serum;
3. Characteristic triad of electromyo-
graphic alterations; 
4. Muscle biopsy evidence;
5 .Characteristic dermatologic features.
Confidence limits were defined as fol-
lows: definite (consisting of 3 or 4 cri-
teria, plus rash), probable (comprising
2 criteria and rash), and possible (in-
cluding 1 criterion and rash) (3).
Thirty-one patients had definite and 7
patients had probable JDM. All of the
adult patients had definite disease. Pa-
tients with a possible diagnosis were
excluded.
Definition of extramuscular and
ex raskeletal manifestations:
At the time of diagnosis, all patients
underwent a clinical evaluation to de-
tect extramuscular nd extraskeletal
manifestations. ECG, chest radiograph
and pulmonary function tests were per-
formed in each case. HRCTand echo-
car iography were carried out if alarm-
ing signs and symptoms were detected
during the physical examination or dur-
ng previous screening tests. Later on in
the clinical course of the disease, these
tests were usually repeated annually or
as required (e.g. if a relapse occurred).
Interstitial lung disease (ILD) was con-
sidered to be present if chest radio-
gr ph and/or high-resolution computed
tomography (HRCT) scan indicated bi-
basilar interstitial fibrosis or alveolar
infiltrates and pulmonary function tests
showed abnormalities characterized by
a restrictive pattern.
Diagnosis of cardiac involvement was
based upon the exclusion of other caus-
es of rhythm disturbances, conduction
defects, myocarditis, cardiomyopathy
and congestive heart failure.
Respiratory muscle involvement is a
res lt of weakness of the respiratory
musculature in DM and it was consid-
ered to be present if patients exhibited
ventilatory failure with decreased vital
capacity.
Disease course
Patients were classified into 4 groups
based on their disease course: (i) fulmi-
nant onset disease, (ii) monophasic,
(iii) polycyclic and (iv) chronic. In ful-
minant onset disease, life-threatening
events occurred which led to death.
The disease course was considered to
be monophasic if a single episode of
the disease occurred, but recovery was
achieved and the patient remained free
of symptoms and laboratory changes
associated with the disease. The dis-
ease course was regarded as polycyclic
if the patient had more than one epi-
sode, but between relapses remission
was achieved (relapsing-remitting dis-
ease). A chronic-progressive course
was defined by a partial response to
ther py with failure to achieve remis-
sion 24 months after the diagnosis.
The disease course and response to
treatment were assessed by physical
examination and changes in the levels
of serum muscle enzymes. Remission
was defined as: (i) stable improvement
or normalization of muscle strength,
(ii) normalization of serum CK and/or
LDH activity, and (iii) the disappear-
ance of cutaneous changes. A r lapse
was defined as disease reactivation af-
ter a remission lasting 6 months or
more.
Considering the retrospective and mul-
ic nter design of our study and the re-
sults of previously reported investiga-
tions, finding no correlation between re-
lapses and disease severity (12), we de-
cided not to assess the severitiy (acti-
vi y) of the disease. While relapses can
be develop after a prolonged disease-
free interval, the probability of a mono-
phasic course was determined in each
case with only one episode of the dis-
ease.
Duration of follow-up and end-points
Data collection was terminated by
April 1, 2003, when the present study
was performed. The duration of follow-
up was determined from time 0 corre-
sponding to the date of diagnosis to ei-
ther the date of death or to the date of
the latest appearance at our depart-
ments (end-points). The median fol-
low-up for patients with JDM was 32
months (range: 4.5– 360.5; 25th per-
centile: 12.0 and 75th percentile: 69.4).
Twelve patients were followed up for a
minimum of 5 years out of our 38 JDM
patients. None of the juvenile patients
in our study have died. In the group of
adult patients with primary DM, the
median duration of follow-up was 78
months (range: 4–248; 25th percentile:
39 and 75th percentile: 107.43) for sur-
viving patients. Nineteen adult patients
we  followed up more than 5 years
and 6 adult patients were followed up
more than 10 years. Four disease-relat-
ed deaths occurred and the duration of
follow up was 1.8, 3.45, 0.79 and 92.9
months for the patients who died due to
DM. The causes of death were record-
ed in an autopsy (5 patients) or death
cer ificate (1 patient).
Statistical analysis
Data were analyzed using the Statistica
6.0 statistics software. Probability of a
monophasic clinical course and  sur-
vival curves were drawn using the Kap-
lan-Meier method. The log-rank test
was used to determine the statistical sig-
nificance of the observed differences in
survival rates between patient groups.
We decided not to consider prognostic
factors due to the fact that the number
of events was insufficient to analyze
the effect of any clinical features char-
acteristic of DM on survival. Pvalues £
0.05 were considered significant.
Results
Clinical characteristics of our DM
patients
The clinical characteristics of our co-
hort of juvenile and adult DM patients
are presented in Table II. There were
more males than females in the group
of juvenile patients. Extramuscular and
extraskeletal manifestations of the dis-
ease were more frequent in adult pa-
tients. Only one JDM patient had ILD,
and cardiac manifestations of the dis-
ease or respiratory muscle involvement
were not observed in juvenile patients.
Respiratory muscle involvement and
ILD were more frequent among adult
DM patients than the cardiac manifes-
tation of the myositis.
Treatment and clinical course of our
DM patients
Initially 37 JDM patients were treated
with glucocorticoids. Twelve of them
( 2 0 / 3 7 ,54.1%, CI: 36.9–70.5%) re-
sponded to glucocorticoids and achiev-
ed remission, while  4/37 (10.8%, CI: 0.3
–21.3%) patients received AZAduring
which time the glucocorticoid was
tapered. 13/37 (35.1%, CI: 19.0–5 1 . 3 % )
were administered other second-line
immunosuppressive agents and low dose
glucocorticoids (in 6 cases with CYA
and in 7 cases with MTX). A m o n g
these, 10 patients achieved remission
while disease course of 3 patients be-
came chronic. Only one patient was
treated with intravenous immunoglob-
ulin (IVIG). Data on this child was
excluded from the analysis based on
therapy.
In the group of adult DM patients,
20/35 (57.1%, CI: 39.3-73.7%) achiev-
ed remission on glucocorticoids alone.
15/35 patients (48.9%, CI: 26.3-60.6%)
required additional immunosuppres-
sive agents as initial therapy. 10/35 pa-
tients were administered glucocorti-
coids+CYA (among them, IVIG was
also added in 4 cases, and in 1 case
AZA was added). Two patients were
treated with glucocorticoids and IVIG.
One patient was given glucocorticoid
and ritrosulfan (a Hungarian immuno-
suppressive drug, Lycurim) and 1 pa-
tient was treated with glucocorticoid +
AZA. One patient was died, despite at-
tempted treatment with the entire ther-
apeutic arsenal (glucocorticoid, AZA,
CYC, IVIG and plasmapheresis).
The disease course of 23/38 patients
(54.8%, CI: 43.4– 76.0%) with JDM
was classified as monophasic (the pro-
bability of monophasic disease was 77-
100%, median: 93%). 12/38 patients
(31.6%, CI: 17.5–48.7%) had a poly-
cyclic clinical course and 3/38 patients
(7.9%, CI: 1.6-21.3%) had chronic dis-
ease. In the group of 35 patients with
adult DM, 18 (51.4%, CI: 33.9-68.6%)
patients had monophasic disease (the
probability of monophasic disease was
63-100%, median: 81%); 13 (37.1%,
CI: 21.5– 55.1%) had polycyclic dis-
ease; one (2.9%, CI: 0.07–14.9%) had
chronic disease; and 3 (8.6%, CI: 1.8-
23.1%) had acute fulminant myositis.
Difference between initial treatment
regimens
To investigate the difference between
the initial treatment and that following
disease course, we divided patients into
two groups based on which therapy led
to remission: glucocorticoid alone or
glucocorticoid and second-line immun-
osuppressive agent(s).
Twelve of 37 patients with JDM
( 4.1%, CI: 36.9–70.5%) were admin-
istered glucocorticoids, which led to
remission. In this group, 12/20 (60%,
CI: 36.1– 81.0%) children had mono-
phasic disease (the probability of mon-
ophasic disease: 61-100%, median:
100%), and 8/20 (40%, CI: 19.1-
64.0%) had polycyclic disease (number
of relapses: 1-4, mean: 1.9).
Seventeen of 37 JDM patients received
second-line immunosuppressive agents
with glucocorticoids as the initial treat-
ment. Among these patients, 10/17
(58.8%, CI: 33.0-81.5%) had mono-
pha ic (the probability of monophasic
disease: 79-100%, median: 83.5%),
4/17 (23.5%, CI: 6.8-50.0%) had poly-
cyclic (number of relapses: 1-2, mean:
1.25) and 3/17 (17.7%, CI: 38.0-
43.4%) had chronic disease.
Among adult DM patients requiring
only glucocorticoids as the initial treat-
ment, 12/20 cases of monophasic
(60%, CI: 36.1-80.8%, the probability
of monophasic disease: 65-100%,
median: 81%) and 8/20 cases of poly-
cyclic (40%, CI: 19.1-63.9%, number
of relapses: 1-8, mean: 3.25) disease
were observed. In the second group,
where second-line immunosuppressive
agents were required, 3/15 patients
(20%, CI: 4.3-48.1%) had acute fulmi-
nant myositis;  6/15 patients were mo-
nophasic (40%, CI: 16.3-67.7%, the
probability of monophasic disease: 63-
100%, median: 78%); 5/15 patients
were polycyclic (33.3%, CI: 11 . 8 -
61.6%, number of relapses: 1-3, mean:
2.2); and 1/15 patients had chronic dis-
ease (6.67%, CI: 0.01-31.9%).
Disease course and survival of JDM and DM patients /A. Ponyi et al. 
53
Table II.Demographic and clinical features of our patients with juvenile (JMD) or adult
dermatomyositis (DM).
JDM DM
Number of patients 38 35
Mean age at the time of dignosis 8.6 yrs. (3-16) 44.0 yrs. (22-71)
Male:female ratio 1:1.7 1:2.5
Median duration of follow up time32 month (4.5-360.5) 78 month (4.0-248.0)
ILD 2.4% (0.07-13.8%) 22.8% (CI: 10.4-40.1%)
Respiratory muscle involvement 0% 17.1% (CI: 6.6-33.5%)
Cardiac manifestation 0% 8.6% (CI:1.8-23.1%)
JDM: juvenile dermatomyositis; DM: dermatomyositis; ILD: interstitial lung disease; CI: confidence
interval.
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Relapse rate of our DM patients
A polycyclic (remitting-relapsing) dis-
ease course was observed in 12/38
juvenile patients (31.6%, CI: 17.5-
48.6%) and in 13/35 adult DM patients
(37.1%, CI: 21.4-55.1%). We plotted
the cumulative relapse-free proportion
of patients against the follow-up time
using the Kaplan-Meier method. A s
shown in Figures 1 and 2, the relapse
rate of the disease during the first year
after the first remission had been
achieved was higher than later in the
course. Among JDM patients with a
polycyclic disease course, the longest
disease-free interval after  first remis-
sion had been achieved was 24 months,
while this interval was 86 months in the
group of adult DM patients. In other
words, among JDM patients relapses
did not develop after a 24-month dis-
ease-free interval and patients remain-
ed in remission.
Survival of our DM patients
None of the juvenile patients in our
study, but 6 patients in our cohort of
adult DM patients died. Nevertheless,
the survival probability was not signifi-
cantly different between JDM and adult
DM patients (Fig. 3). In the group of
adult DM, 1-, 5- and 10-year survival
rates were 91.4% (CI: 82.6-100%),
91.4% and 84.9% (CI: 71.1-100%),
respectively. There were 4 disease-spe-
cific deaths at the age of 28, 49, 54, 61
years, after 1.8, 3.45, 0.79 and 92.9
months of follow-up. Among those
patients who died due to disease-relat-
ed causes, 2 died within 12 months
after the diagnosis and only 1 patient
died more than 5 years after the diagno-
sis of myositis was made. The F:M
ratio of cases ending in mortality was
not similar to the F:M ratio for the dis-
ease itself: 3 were male and only 1 was
female. Causes of death were cardiac
and pulmonary complications (2 cases
of acute heart failure and 2 cases of res-
piratory muscle involvement). Non-
disease specific causes of death were
viral meningitis and liver failure.
Discussion
We report the first study on the disease
course, relapse rate and survival of pa-
tients with JDM who were diagnosed,
treated and followed up in Hungary.
The clinical characteristics of our co-
hort of juvenile and adult DM patients
(distribution of different types, female
to male ratio, age distribution) were si-
milar to those in other series in the lit-
erature (7, 9, 17).
We found that most of the juvenile and
adult patients with DM had a mono-
phasic disease course. The frequency
of the polycyclic (relapsing-remitting)
disease course was similar in both
groups of patients. A chronic disease
course was more frequent among JDM
patients. Huber and colleagues studied
65 JDM patients and found that 24
(37%) patients had a monocyclic course
and 41 (63%) had a chronic continuous
or polycyclic course (6). Phillips et al.
observed a similar frequency of relaps-
s in adults (50-60%) (12).
As shown in Figures 1 and 2, the risk of
lapse was higher during the first year
after remission than later in the disease
course in both the juvenile and adult
p tients. Among adult patients, relaps-
es were found to be more frequent
within the first 24 months after the
diagnosis of the disease (12). Accord-
ing to our results and the literature data,
we must emphasize that patients with
JD  should be followed up for at least
2 y ars even if they are in remission. In
our study, 11 of 24 JDM patients with
monophasic disease were followed up
for less than 24 months. All of them
Fig. 1.Proportion of juvenile patients with dermatomyositis in remission without relapses, with 95%
confidence intervals.
Fig. 2.Proportion of adult patients with dermatomyositis in remission without relapses, with 95% con-
fidence intervals.
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were in remission when the follow-up
period came to an end and we assume
that in the majority of cases this was
due to a complete recovery.
All of the children were given gluco-
corticoids initially, except for one who
received IVIG. 20/38 (52.6%) patients
achieved remission due to classical
glucocorticoid therapy, while 18/38
(47.4%) patients required second-line
agents. This ratio does not differ con-
siderably from the data available in the
literature: 62/65 (95%) patients were
treated with glucocorticoids, while
42/65 (63%) received a second-line
agent in Huber’s cohort of patients (6).
The frequency of a monophasic disease
course was the same among juvenile
and adult patients who received sec-
ond-line immunosuppressive agents
initially, and among juvenile or adult
patients who were given glucocorti-
coids alone. As previously reported by
others, there is no evidence of a corre-
lation between the occurrence of relap-
ses and the initial severity of the dis-
ease or the mean starting dose of gluco-
corticoids (10,12). In this study, we ob-
served no correlation between the ini-
tial therapeutic regimen (glucocorti-
coid alone, or with second-line immu-
nosuppressive agents) and subsequent
relapses.
Survival studies are influenced by sev-
eral factors which can modify the re-
sults considerably, and the observed
differences in mortality rates are attrib-
utable to: (i) the way patients are se-
l cted (diagnostic criteria, recruitment
from a single or more than one center,
whi h subgroups of IIMs are included
in the analysis), (ii) whether a suffi-
cient number of patients have been
recruited and whether data from cases
lost to follow-up are included or not,
and (iii) the duration of follow-up.
Available data on the survival of pa-
tients with IIMs come from the USA,
England, France, and Israel (Table III).
Clinicopathological subgroups of IIMs
included in these studies differ consid-
erably. Therefore, our results are not
exactly comparable with the data in the
relevant literature. The relative size of
the juvenile patient group was the
largest in our study, but we studied only
DM patients. It is also important o
mention that patients with CAM and
overlap myositis were excluded. With
all of these considerations in mind, our
study indicates that patients with juve-
nile and adult DM showed survival
rates similar to those reported in the
international literature. We found no
significant difference between the adult
and juvenile patient groups. The major
causes of death were similar to those
reported by others (5, 18).
In conclusion, no correlation was found
between relapse-free survival and the
initial therapeutic regimen. Consider-
able proportions of juvenile and adult
DM patients have a polycyclic or chro-
nic disease course and often require
continuing medication and follow-up
for many years. Based on our results, as
relapses can occur after a prolonged di-
sease-free interval, JDM and DM pa-
tients should be followed up for at least
2 years, even if they are in remission
and have no signs and symptoms. Fi-
nally, although we found a favourable
survival probability, further investiga-
tions are needed to assess functional
outcome and quality of life.
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